Press Releases

April 24, 2025

Regulatory

Notice of annual general meeting in SynAct Pharma AB

April 23, 2025

Non Regulatory

SynAct receives Notice of Allowance for grant of US Patent covering resomelagon (AP1189) combination therapy

April 16, 2025

Non Regulatory

SynAct Pharma to participate at BIO International Convention in Boston June 16-19

April 11, 2025

Non Regulatory

SynAct Pharma Announces Initiation of Phase II Study with resomelagon (AP1189) for the Treatment of Patients with Dengue

April 10, 2025

Regulatory

SynAct Pharma publishes Annual Report 2024

March 17, 2025

Non Regulatory

The European Patent Office issues an Intention to Grant a European Patent Covering the Clinical Formulation of Resomelagon (AP1189)

March 4, 2025

Non Regulatory

Pivotal US Patent Protecting Resomelagon (AP1189) Granted to SynAct Pharma

February 20, 2025

Regulatory

SynAct’s Nomination Committee proposes Jeppe Ragnar Andersen to the Board

February 18, 2025

Regulatory

SynAct Pharma Year-end Report 2024

January 31, 2025

Regulatory

Change in number of shares and votes in SynAct Pharma AB

January 9, 2025

Regulatory

SynAct Pharma AB resolves on a directed share issue to guarantors

January 9, 2025

Regulatory

SynAct Pharma AB announces outcome of the rights issue